It is becoming increasingly expensive to both obtain patents and defend them in lawsuits should the need arise. An alternative is protecting your right to commercialize an invention through the strategy of defensive publications.

Once in my early days as a bench chemist, lab notebooks were collected to serve as evidence in a patent law suit. This experience put the fear into me. I learned a lesson in all aspects of documentation and in reporting defensible data.

The American Society for Clinical Pathology has announced that the ASCP Board of Registry was awarded accreditation by the American National Standards Institute for a period of five years.

ANSI has created the

Bio-Matrix Scientific Group Inc., a biotechnology company focused on stem cell cryogenics and disposable stem cell / tissue transfer instruments said it progress on its planned 15,000 square foot Stem Cell Bank and Laboratories has

Zogenix, Inc., a privately held neuroscience-focused specialty pharmaceutical company, announced today it has received $3.5 million of a $10 million loan facility with GE Healthcare Financial Services.

Zogenix wi

Nanosys, Inc. and Bruker Daltonics Inc. today announced that they have entered into a broad R&D collaboration and distribution agreement for Nanosys' nanotechnology-enabled matrix-free target plates for use primarily with Bruker's F

The American Society for Clinical Pathology (ASCP), the world's largest organization representing the laboratory team, approved and announced its policy on health information technology/informatics and electronic medical health reco

A $33 million donation will help build a home for Stanford's Institute for Stem Cell Biology and Regenerative Medicine.

Lorry I. Lokey, the founder of Business Wire and a supporter of education and science, will

One of the new requirements in ISO/IEC 17025:2005 is to actively seek the feedback of laboratory customers and do something with it to improve the management system and the technical activities. Fairly ambitious words.

Salix Pharmaceuticals, Ltd. today announced that it has purchased the U.S. prescription pharmaceutical product rights to PEPCID Oral Suspension and DIURIL Oral Suspension from Merck & Co., Inc.

PEPCID Oral Suspens

New England has 42 new facilities scheduled to be completed this year, with a total investment value of $1.2 billion, according to published reports.

When the plants become fully operational an estimated 4,000 job